Plural Ring Nitrogens In The Tricyclo Ring System Patents (Class 514/292)
-
Patent number: 7968562Abstract: Pharmaceutical formulations comprising an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-quinolineamines, oxazolo-quinolinamines, thiazolo-pyridinamines, oxazolo-pyridinamines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Novel topical formulations are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.Type: GrantFiled: July 14, 2008Date of Patent: June 28, 2011Assignee: 3M Innovative Properties CompanyInventors: Raymond D. Skwierczynski, Terri F. Busch, Amy L. Gust-Heiting, Mary Fretland, Matthew T. Scholz
-
Patent number: 7968591Abstract: 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides corresponding to formula I methods for their production, pharmaceutical compositions containing them, and the use thereof for noradrenalin receptor regulation, particularly for inhibiting noradrenalin reuptake, and/or for 5-HT receptor regulation, particularly for inhibiting 5-hydroxy tryptophan reuptake, and/or for opioid receptor regulation and/or for batrachotoxin (BTX) receptor regulation and/or for treating or inhibiting pain and other conditions.Type: GrantFiled: December 9, 2008Date of Patent: June 28, 2011Assignee: Gruenenthal GmbHInventors: Stefan Oberboersch, Bernd Sundermann, Corinna Sundermann, Edward Bijsterveld, Hagen-Heinrich Hennies
-
Publication number: 20110152308Abstract: The present application relates to indole and indoline derivatives of formula (I) wherein a, R1, m, L, and Q are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions of such compounds.Type: ApplicationFiled: December 14, 2010Publication date: June 23, 2011Applicant: ABBOTT LABORATORIESInventor: Lei Shi
-
Publication number: 20110152309Abstract: There is provided a pharmaceutical agent, food, or beverage for treating or preventing a disease or condition that can be ameliorated by inhibiting serotonin reuptake, comprising a clinically-effective amount of (1S,3S)-1-methyl-1,2,3,4-tetrahydro-?-carboline-3-carboxylic acid.Type: ApplicationFiled: August 6, 2009Publication date: June 23, 2011Applicant: SUNTORY HOLDINGS LIMITEDInventors: Yoshinori Beppu, Nobuo Tsuruoka, Hajime Komura
-
Publication number: 20110144074Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.Type: ApplicationFiled: January 24, 2011Publication date: June 16, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Michael Mortimore, Andrew Miller, John Studley, Jean-Damien Charrier
-
Publication number: 20110136853Abstract: The present invention is directed to the novel ligand with wide range of pharmacological activity including activity to GPCR receptors, ion channels and monoamine transporters representing 3-methyl-9-benzyl-1,2,3,4-tetrahydrocarboline naphthalene-1,5-disulfonate of formula 1 The invention is also directed to the novel drug substance, Pharmaceutical formulation comprising the novel drug substance, and to the method for its preparation, to the novel medicaments, and method for treatment of CNS diseases including neurodegenerative diseases and cognitive disorders at humans and warm blooded animals.Type: ApplicationFiled: August 3, 2009Publication date: June 9, 2011Inventors: Andrey Alexandrovich Ivaschenko, Nikolay Filippvich Savchuk, Alexander Vasilievich Ivashchenko
-
Patent number: 7956064Abstract: The invention relates in part to fused tricyclic compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. The fused tricyclic compounds of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such fused tricyclic compounds.Type: GrantFiled: August 31, 2007Date of Patent: June 7, 2011Assignee: Cylene Pharmaceuticals, Inc.Inventors: Peter C. Chua, Jeffrey P. Whitten
-
Patent number: 7951949Abstract: The present invention is directed to macrocyclic aminopyridyl compounds represented by general formula (I), which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.Type: GrantFiled: November 18, 2005Date of Patent: May 31, 2011Assignee: Merck, Sharp & Dohme, Corp.Inventors: Philippe G. Nantermet, Hemaka A. Rajapakse, Harold G. Selnick, Keith P. Moore
-
Publication number: 20110123586Abstract: Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.Type: ApplicationFiled: June 2, 2009Publication date: May 26, 2011Inventors: Bonnie Bassler, Lee Swem
-
Publication number: 20110118299Abstract: The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic-i), e.g., NFD-L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Applicant: The University of Kentucky Research FoundationInventors: Mark Lovell, Bert Lynn
-
Publication number: 20110112106Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.Type: ApplicationFiled: January 7, 2011Publication date: May 12, 2011Applicant: Amira Pharmaceuticals, Inc.Inventors: John Howard HUTCHINSON, Thomas Jonathan SEIDERS, Brian Andrew STEARNS, Bowei WANG, Jill Melissa SCOTT, Yen Pham TRUONG
-
Publication number: 20110112134Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: ApplicationFiled: January 15, 2009Publication date: May 12, 2011Applicant: AMIRA PHARMACEUTICALS, INC.Inventors: John Howard Hutchinson, Brian Andrew Stearns, Ryan Clark
-
Publication number: 20110112133Abstract: A compound represented by the formula (I) wherein A is a benzene ring optionally having substituent(s), R is a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s), X1 and X2 are each a bond or a divalent C1-5 chain hydrocarbon group optionally having substituent(s), X3 is a methylene group having substituent(s), Y is a bond or the like, and Z is a hydrocarbon group optionally having substituent(s) or the like, or a salt thereof. The compound of the present invention or a salt thereof is useful as an NK receptor antagonist.Type: ApplicationFiled: November 1, 2010Publication date: May 12, 2011Applicant: Takeda Pharmaceutical Company LimitedInventors: Kasei Miura, Yuji Nishikimi
-
Publication number: 20110112132Abstract: A means for the treatment of insult based on hydrogenated pyrido(4,3-b)indoles (variants) of formula (1) or formula (2) a pharmacological means based thereon and a method for the use thereof relate to the use of chemical compounds in the field of medicine and may be used for the treatment of ischemic and hemorrhagic insults and their consequences.Type: ApplicationFiled: November 30, 2007Publication date: May 12, 2011Inventors: Sergey Olegovich Bachurin, Taisiya Leonovna Garibova, Tatiana Alexandrovna Voronina, Vladimir Viktorovich Grigoriev
-
Publication number: 20110105474Abstract: This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1 C6 haloalkoxy; R2, R3 are, independently, hydrogen; C1-C6 alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH2)mCR4R5(CH2)n, or (CH2)oNR6(CH2)p; m, n, o, p, R4, R5 and R6 are as further defined in the specification; and pharmaceutical acceptable salts thereof.Type: ApplicationFiled: June 8, 2009Publication date: May 5, 2011Inventors: Florian Thaler, Mario Varasi, Stefania Gagliardi, Andrea Colombo, Saverio Minucci, Ciro Mercurio
-
Publication number: 20110092534Abstract: A compound having the general the general structure I is provided: (Formula I), wherein Z is a substituent selected from a group consisting of S and O; X is a substituent selected from a group consisting of Cl, Br, I, OH and NH2; each of R1 and R2 is a substituent independently selected from a group consisting of H, a linear, cyclic or branched, substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl; and each of Y and Y1 is a substituent independently selected from a group consisting of H and C(O)—C6H4—Br.Type: ApplicationFiled: June 27, 2008Publication date: April 21, 2011Inventors: William Fenical, Paul Jensen, John Macmillan, Chambers C. Hughes, James J. Laclair
-
Publication number: 20110081365Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.Type: ApplicationFiled: February 27, 2009Publication date: April 7, 2011Applicants: IRM LLC, Novartis 35Inventors: Alex Cortez, Yongkai Li, Pranab Mishra, Manmohan Singh, David Skibinski, Nicholas Valiante, Tom Yao-Hsiang Wu, Xiaoyue Zhang, Yefen Zou
-
Patent number: 7919636Abstract: Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds.Type: GrantFiled: June 20, 2008Date of Patent: April 5, 2011Assignee: The Regents of the University of CaliforniaInventors: Navindra P. Seeram, David Heber
-
Patent number: 7915280Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.Type: GrantFiled: August 30, 2005Date of Patent: March 29, 2011Assignee: Eisai Inc.Inventors: Dana Victor Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang
-
Publication number: 20110071155Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof: wherein: one of Z1 and Z2 is CH or N and the other is CH; L is selected from: —CH2—CH?CH—, —CH?CH—CH2—, —(CH2)p— where p is 2, 3 or 4, —CH2—CH2—O—, —O—CH2—CH2—, —CH2—CH2—NH—, —HN—CH2—CH2—, —C(O)—CH?CH—, —CH?CH—C(O)—, —CH2—C?C— or —C?C—CH2—; U represents a cyclic group; m is 0 or 1, n is independently 0 or 1; and substituent(s) R5 and R6 are independently selected from: halo, CF3, OCF3, C1-3 alkyl, C1-3 alkoxy, nitro and cyano, pharmaceurtical compositions comprising them, their use in therapy especially against tuberculosis, and methods of preparing them.Type: ApplicationFiled: May 20, 2009Publication date: March 24, 2011Inventors: Carlos Alemparte-Gallardo, David Barros-Aguirre, Monica Cacho-Izquierdo, Jose Maria Fiandor Roman, Modesto Jesus Remuinan-Blanco
-
Publication number: 20110071136Abstract: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.Type: ApplicationFiled: September 16, 2010Publication date: March 24, 2011Applicant: CYLENE PHARMACEUTICALS, INCInventors: Mustapha HADDACH, Fabrice PIERRE
-
Publication number: 20110071174Abstract: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim 1: and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.Type: ApplicationFiled: May 13, 2009Publication date: March 24, 2011Inventors: Bernard Golding, Richard Franklin
-
Patent number: 7910600Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.Type: GrantFiled: August 29, 2008Date of Patent: March 22, 2011Assignee: Cylene Pharmaceuticals, Inc.Inventors: Fabrice Pierre, Mustapha Haddach
-
Publication number: 20110059999Abstract: The invention relates to compounds which have an affinity for the ? opioid receptor and the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.Type: ApplicationFiled: September 22, 2010Publication date: March 10, 2011Applicant: GRÜNENTHAL GMBHInventors: Sven Frormann, Saskia Zemolka, Klaus Linz, Werner Englberger, Fritz Theil
-
Publication number: 20110053925Abstract: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, ring A, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.Type: ApplicationFiled: August 27, 2010Publication date: March 3, 2011Inventors: Young Shin CHO, Lei JIANG, Michael SHULTZ, Christine Hiu-Tung CHEN, Gang LIU, Jianke LI
-
Publication number: 20110053906Abstract: Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.Type: ApplicationFiled: February 25, 2009Publication date: March 3, 2011Applicant: MERCK PATENT GMBHInventors: Bayard R. Huck, Xiaoling Chen, Lizbeth Celeste Deselm, Christopher Charles Victor Jones, Srinivasa R. Karra, Yufang Xiao, Andreas Goutopoulos, Amanda E. Sutton
-
Patent number: 7897597Abstract: Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.Type: GrantFiled: August 27, 2004Date of Patent: March 1, 2011Assignee: 3M Innovative Properties CompanyInventors: Kyle J. Lindstrom, Hugues M. H. Martin, Bryon A. Merrill, Michael J. Rice, Joshua R. Wurst, Chad A. Haraldson, Tushar A. Kshirsagar, Philip D. Heppner, Shri Niwas, George W. Griesgraber, Matthew R. Radmer
-
Patent number: 7897767Abstract: Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.Type: GrantFiled: November 12, 2004Date of Patent: March 1, 2011Assignee: 3M Innovative Properties CompanyInventors: Tushar A. Kshirsagar, Gregory D. Lundquist, David T. Amos, Joseph F. Dellaria, Jr., Bernhard M. Zimmermann, Philip D. Heppner
-
Patent number: 7897791Abstract: Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds.Type: GrantFiled: December 24, 2009Date of Patent: March 1, 2011Assignee: The Regents of the University of CaliforniaInventors: Navindra P. Seeram, David Heber
-
Publication number: 20110046130Abstract: The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.Type: ApplicationFiled: March 27, 2009Publication date: February 24, 2011Applicant: Evotec AGInventors: Adam James Davenport, David James Hallett, Frédéric Marlin, Mark Gemkow
-
Publication number: 20110046174Abstract: The present invention concerns methods useful in treating a subject having diarrhea-predominant IBS (IBS-D) by administering N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof to the subject.Type: ApplicationFiled: November 5, 2010Publication date: February 24, 2011Applicant: Tioga Pharmaceuticals, Inc.Inventor: Allen MANGEL
-
Patent number: 7893082Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.Type: GrantFiled: May 17, 2006Date of Patent: February 22, 2011Assignee: Merck Patent GmbHInventors: Kai Schiemann, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Nina Heiss, Frank Zenke
-
Publication number: 20110039825Abstract: The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously ?-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C1-C4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, CF3, CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH2)m group, optionally substituted CH?CH group, optionally substType: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Applicant: Alla Chem, LLCInventors: Andrey Alexandrovich Ivashchenko, Vasilievich Ivashchenko, Yan Vadimovich Lavrovsky, Oleg Dmitrievich Mitkin, Nikolay Filippovich Savchuk, Sergey Yevgenievich Tkachenko, Ilya Matusovich Okun
-
Publication number: 20110039832Abstract: The invention relates to 5,6-dihydropyrrolo[2,1-a]isoquinoline and pyrrolo[2,1-a]isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.Type: ApplicationFiled: February 6, 2009Publication date: February 17, 2011Applicant: N.V. OrganonInventors: Rachel Deborah van Rijn, Hubert Jan Josef Loozen, Cornelis Marius Timmers, Lar Anders van der Veen, Willem Frederik Johan Karstens
-
Publication number: 20110028462Abstract: A method of treating atherosclerosis and related conditions using compounds of formula I: as well as pharmaceutically acceptable salts and solvates is disclosed. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels.Type: ApplicationFiled: September 15, 2006Publication date: February 3, 2011Inventors: Steven L. Colletti, Jason E. Imbriglio, Richard Thomas Beresis, Jessica Leslie Frie
-
Publication number: 20110028445Abstract: The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 ?-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.Type: ApplicationFiled: February 10, 2009Publication date: February 3, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Matthias Eckhardt, Frank Himmelsbach, Bradford S. Hamilton, Stefan Peters
-
Patent number: 7879859Abstract: The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.Type: GrantFiled: November 17, 2006Date of Patent: February 1, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Yun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
-
Publication number: 20110021554Abstract: An aqueous parenteral pharmaceutical formulation of the IRM drug compound N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide dissolved in water, buffer selected from citric acid, acetic acid, lactic acid, succinic acid, and tartaric acid, and optionally a tonicity adjuster, preferably selected from sorbitol and mannitol, wherein the pH is no greater than 6 and the formulation is sterile and preferably substantially free of sodium chloride.Type: ApplicationFiled: September 29, 2010Publication date: January 27, 2011Inventors: James D. Stoesz, Cynthia A. Guy
-
Publication number: 20110015217Abstract: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.Type: ApplicationFiled: January 11, 2010Publication date: January 20, 2011Inventors: STEVEN L. MCKNIGHT, ANDREW A. PIEPER, JOSEPH M. READY, JEF K. DE BRABANDER
-
Patent number: 7872014Abstract: The present invention comprises compounds and pharmaceutical compositions comprising the compounds that are inhibitors of ALK. The invention also comprises methods of using the compounds and compositions to treat diseases mediated by ALK, including diseases such as cancer, immunological disorders, cardiovascular diseases, and other degenerative disorders.Type: GrantFiled: July 23, 2004Date of Patent: January 18, 2011Assignee: Exelixis, Inc.Inventors: Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Joerg Bussenius, Simona Costanzo, Jeffry Kimo Curtis, Larisa Dubenko, Abigail R. Kennedy, Richard G. Khoury, Angie I. Kim, Jean-Claire L. Manalo, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang
-
Publication number: 20110008278Abstract: The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound. selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, ?-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (RMPA), kainic acid and glutamic acid, wherein the effective amount of the compound induces paraptotic death of the cell. The invention further is directed to a method of inhibiting paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of Alg-2-interacting protein 1 (AIP-1), Jun N-terminal kinase 1 (JNK1) neutralizing agent, Jun N-terminal kinase 2 (JNK2) neutralizing agent, TNF Receptor-Associated Factor 2 (TRAF2) neutralizing agent, ortho-phenanthroline and the JNK inhibitor SP 600125, wherein the effective amount of the compound inhibits paraptotic death of the cell.Type: ApplicationFiled: February 5, 2010Publication date: January 13, 2011Inventors: Sabina SPERANDIO, Dale E. Bredesen
-
Publication number: 20110009378Abstract: The present invention relates to heterocyclic compounds of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such heterocyclic compounds, and the use of such heterocyclic compounds for therapeutic purposes.Type: ApplicationFiled: February 16, 2010Publication date: January 13, 2011Applicant: Abbott GmbH & Co. KGInventors: Udo Lange, Andreas Heutling, Wilhelm Amberg, Michael Ochse, Berthold Behl, Wilfried Hornberger, Mario Mezler
-
Publication number: 20110003788Abstract: The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula (I) wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR1 (R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R2 is carbamoyl optionally having substituent(s); and R3 is hydroxy optionally having substituent(s), or a salt thereof.Type: ApplicationFiled: February 25, 2009Publication date: January 6, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Nobuhiro Fujii, Yuya Oguro, Satoshi Sasaki, Shigeru Kondo
-
Publication number: 20110002855Abstract: Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues of the formula (I): are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).Type: ApplicationFiled: June 25, 2008Publication date: January 6, 2011Applicant: NEUROGEN CORPORATIONInventors: Timothy M. Caldwell, Yang Gao, Linghong Xie, Yuelian Xu
-
Publication number: 20110003836Abstract: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protection from neuron cell death.Type: ApplicationFiled: July 7, 2010Publication date: January 6, 2011Inventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander
-
Publication number: 20100331318Abstract: The invention relates to antibacterial compounds of formula I wherein n is 0 or 1; R1 represents H or F; U represents CH2 or, provided n is 1, O or NH; “-----” is a bond or is absent; V represents CH or N when “-----” is a bond, or CH2 or NH when “-----” is absent; W represents CH or N; A represents —(CH—)p—NH—(CH2)q— wherein p is 1 and q is 1 or 2 or, provided U represents CH2 and n is 1, p may also be 0 and q is then 2; G represents one of the groups wherein Z represents N or CH and Q represents O or S; and Z0, Z1 and Z2 each represent CH, or Z0 and Z1 each represent CH and Z2 represents N, or Z0 represents CH, Z1 represents N and Z2 represents CH or N, or Z0 represents N and Z1 and Z2 each represent CH; and to salts of such compounds.Type: ApplicationFiled: February 19, 2009Publication date: December 30, 2010Applicant: Actelion Pharmaceuticals Ltd.Inventors: Christian Hubschwerlen, Georg Rueedi, John-Philippe Surivet, Cornelia Zumbrunn-Acklin
-
Publication number: 20100331357Abstract: The present invention provides a pharmaceutical composition, wherein solubility and stability of a water-insoluble or slightly water-soluble compound represented by formula (I): wherein each symbol is as defined in the specification, are improved, by combination of the above-mentioned compound and a cyclodextrin derivative and a method for improving solubility, stability and the like of the above-mentioned compound.Type: ApplicationFiled: February 27, 2009Publication date: December 30, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tomomichi Futo, Shinichiro Nakai, Rinaldo Laurentius De Jong, Bumsup Lee, Ronald Joseph Christopher
-
Publication number: 20100331339Abstract: Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5; is H, optionally substituted alkyl, optionally substituted heterocycle, —C(?O)—R6, —C(?O)—O—R7, or —C(?O)—NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is —CH2—O—, —CH2CH2—, —CH?CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.Type: ApplicationFiled: January 9, 2009Publication date: December 30, 2010Applicant: ALBANY MOLECULAR RESEARCH, INC.Inventors: Peter Robert GUZZO, Matthew David SURMAN, Alan John HENDERSON, May Xiaowu JIANG, Mark Hadden, James Grabowski, Alexander Usyatinsky
-
Patent number: 7858637Abstract: This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.Type: GrantFiled: June 29, 2009Date of Patent: December 28, 2010Inventor: Devron R. Averett
-
Publication number: 20100324021Abstract: The invention relates to imidazoiso[5,1-a]quinoline and 5,6-dihydro-imidazoiso[5,1-a]quinoline derivatives according to general Formula I or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.Type: ApplicationFiled: May 25, 2010Publication date: December 23, 2010Applicant: N.V. OrganonInventors: Hubert Jan Jozef Loozen, Cornelius Marius Timmers